KIR Donor Selection: Feasibility in Identifying better Donors

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Daniel J Weisdorfparticipating center writing committee

Abstract

We previously reported that acute myelogenous leukemia (AML) transplants using killer cell immunoglobulin-type receptor (KIR) B haplotype better or best (≥2 B activating gene loci ± Cen B/B) unrelated donors (URDs) yield less relapse and better survival. In this prospective trial we evaluated 535 AML searches from 14 participating centers with centralized donor KIR genotyping for donor selection. This represented 3% to 48% of all AML searches (median 20%) per center, totaling 3 to 172 patients (median 22) per center. Donor KIR genotype was reported at a median of 14 days after request (≤26 days for 76% of searches). In 535 searches, 2080 donors were requested for KIR genotyping (mean 4.3 per search); and a median of 1.8 (range, 0 to 4.5) per search were KIR typed. Choosing more donors for confirmatory HLA and KIR haplotype identification enriched the likelihood of finding KIR better or best donors. The search process identified a mean of 30% KIR better or best donors; the success ranged from 24% to 38% in the 11 centers enrolling ≥8 patients. More donors requested for KIR genotyping increased the likelihood of identifying KIR better or best haplotype donors. Of the 247 transplants, 9.3% used KIR best, 19% used KIR better, and 4...Continue Reading

Citations

Nov 23, 2019·International Journal of Immunogenetics·Matthew D Blunt, Salim I Khakoo
Feb 9, 2020·International Journal of Immunogenetics·Alexander H SchmidtJohannes Schetelig
Apr 7, 2019·Bone Marrow Transplantation·Rafael F DuarteUNKNOWN European Society for Blood and Marrow Transplantation (EBMT)
Feb 7, 2020·HLA : Immune Response Genetics·Chen ChenFaming Zhu
Feb 11, 2021·International Journal of Immunogenetics·Ann-Margaret LittlePaul A Wright
Jun 13, 2021·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lisbeth A GuethleinPeter Parham

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.